D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

Biological Psychiatry

Volumn 57, Issue 6, 2005, Pages 577-585

  Heresco Levy, Uriel ^a,b   Javitt, Daniel C ^d,e   Ebstein, Richard ^c   Vass, Agnes ^a   Lichtenberg, Pesach ^a   Bar, Gali ^a   Catinari, Sara ^a   Ermilov, Marina ^a  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; D serine; NMDA receptor; Schizophrenia

Indexed keywords

DEXTRO SERINE; OLANZAPINE; RISPERIDONE; SERINE;

AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEGATIVE SYNDROME; NEPHROTOXICITY; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 15444377601     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.12.037     Document Type: Article

References (49)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Press Washington, DC
2. N. Andreasen Scale for the Assessment of Negative Symptoms (SANS) 1981 University of Iowa Iowa City
3. F.A. Carone, S. Nakamura, B. Goldman Urinary loss of glucose, phosphate, and protein by diffusion into proximal straight tubules injured by D-serine and maleic acid Lab Invest 52 1985 605 610
4. P.C. Contreras D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia Neuropharmacology 29 1990 291 293
5. C.W. Cotman, D.T. Monaghan, A.H. Ganong Excitatory amino acids and neurotransmission NMDA receptor and Hebb-type synaptic plasticity Ann Rev Neurosci 11 1988 61 80
6. J.T. Coyle The glutamatergic dysfunction hypothesis for schizophrenia Harv Rev Psychiatry 3 1996 241 253
7. A.E. Evins, E. Amico, T.A. Posover, R. Toker, D.C. Goff D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia Schizophrenia Res 56 2002 19 23
8. A.E. Evins, S.M. Fitzgerald, L. Wine, R. Roselli, D.C. Goff A placebo controlled trial of glycine added to clozapine in schizophrenia Am J Psychiatry 157 2000 826 828
9. D.C. Goff, D.C. Henderson, A. Evins Eden, D. Amico A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia Biol Psychiatry 45 1999 512 514
10. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D.A. Schoenfeld A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatry 56 1999 21 27
11. D.C. Goff, G. Tsai, D.S. Manoach, J.T. Coyle Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia Am J Psychiatry 152 1995 1213 1215
12. W. Guy ECDEU Assessment Manual for Psychopharmacology 1976 US Department of Health, Education and Welfare Washington, DC
13. K. Hashimoto, T. Fukushimo, E. Shinizu, N. Komatsu, H. Watanabe, N. Shinoda Decreased serum levels of D-serine in patients with schizophrenia Arch Gen Psychiatry 60 2003 572 576
14. A. Hashimoto, T. Nishikawa, R. Konno, A. Niwa, Y. Yasumura, T. Oka Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase Neurosci Lett 152 1993 33 36
15. A. Hashimoto, T. Oka Free D-aspartate and D-serine in the mammalian brain and periphery Prog Neurobiol 52 1997 325 353
16. U. Heresco-Levy Amino acid transmitter systems in schizophrenia and other psychotic disorders H. D'haenen J.A. den Boer M. Westenberg P. Willner Biological Psychiatry 2002 John Wiley & Sons London 587 600
17. U. Heresco-Levy, M. Ermilov, P. Lichtenberg, G. Bar, D.C. Javitt High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia Biol Psychiatry 55 2004 165 171
18. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapiro, G. Silipo, D.C. Javitt Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine and risperidone in schizophrenia Am J Psychiatry 159 2002 480 482
19. U. Heresco-Levy, D.C. Javitt Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia A retrospective analysis Schizophr Res 66 2004 89 96
20. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatry 56 1999 29 36
21. H. Iwama, K. Takahashi, S. Kure Depletion of cerebral D-serine in non-ketotic hyperglycinemia Possible involvement of glycine cleavage system in control of endogenous D-serine Biochem Biophys Res Commun 231 1997 793 796
22. D.C. Javitt, S.R. Zukin Mechanisms of phencyclidine (PCP)-N-methyl-D- aspartate (NMDA) receptor interaction Implications for schizophrenia S.C. Schultz C.A. Tamminga Schizophrenia Research Progress 1991 Raven Press New York 12 18
23. J.P. Kaltenbach, C.E. Ganote, F.A. Carone Renal tubular necrosis induced by compounds structurally related to D-serine Exp Mol Pathol 30 1979 209 214
24. S.R. Kay, L.A. Opler, A. Fiszbein Positive and Negative Syndrome Scale (PANSS) Rating Manual 1987 Social and Behavioral Sciences Documents San Rafael, California
25. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Psychotomimetic, perceptual, cognitive and neuroendocrine responses Arch Gen Psychiatry 51 1994 199 214
26. A.C. Lahti, H.H. Halcomb, D.R. Medoff, C.A. Tamminga Ketamine activates psychosis and alters limbic blood flow in schizophrenia Neuroreport 6 1995 869 872
27. J.P. Lindenmayer, R. Bernstein-Hyman, S. Grochowski Five-factor model of schizophrenia Initial validation J Nerv Ment Dis 182 1994 631 638
28. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, K. Elgen The UKU Side Effect Rating Scale A new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Supp 334 1987 1 100
29. E.D. Luby, B.D. Cohen, F. Rosenbaum, J. Gottlieb, R. Kelley Study of a new schizophrenomimetic drug, Sernyl Arch Neurol Psychiatry 81 1959 363 369
30. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150
31. A.K. Malhotra, D.A. Pinals, H. Weingartner, K. Sirocco, C.D. Missar, D. Pickar NMDA receptor function and human cognition The effects of ketamine in healthy volunteers Neuropsychopharmacology 14 1996 301 307
32. S.R. Marder, S.M. Essock, A.L. Miller, R.W. Buchanan, J.M. Davis, J.M. Kone The Mount Sinai conference on the pharmacotherapy of schizophrenia Schizophr Res 28 2002 5 16
33. D. McNamara, R. Dingledine Dual effects of glycine on NMDA-induced neurotoxicity in rat cortical cultures J Neurosci 10 1990 3970 3976
34. J.P. Mothet, A.T. Parent, M. Wolosker, R. Brady Jr, D.J. Liden, C.D. Ferris D-serine is an endogenous ligand for the glycine site of the N-methy-D-aspartate receptor Proc Natl Acad Sci U S A 59 2000 4926 4931
35. Y. Nagata, R. Konno, A. Niwa Amino acid levels in D-alanine-administered mutant mice lacking D-amino acid oxidase Metabolism 9 1994 1153 1157
36. W.M. Oldendorph Brain uptake of radio labeled amino acids, amines and hexoses after arterial injection Am J Physiol 221 1971 1629 1639
37. J.W. Olney, N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 1995 998 1007
38. J.E. Overall, D.E. Gorham The Brief Psychiatric Rating Scale Psychol Rep 10 1961 799 812
39. I.C. Reid, R.G.M. Morris NMDA receptor and learning A framework for classifying some recent studies B.S. Meldrum F. Moroni R.P. Simon J.H. Woods Excitatory Amino Acids 1991 Raven Press New York 521 532
40. R.B. Rosse, S.K. Thuet, M. Banay-Schwartz, M. Leighton, E. Scarcella, C.G. Cohen Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia An open-label pilot study Clin Neuropharmacol 12 1989 416 424
41. S. Shoham, D.C. Javitt, U. Heresco-Levy Chronic high-dose glycine nutrition Effects on rat brain cell morphology Biol Psychiatry 49 2001 876 885
42. S. Shoham, H. Mazeh, D.C. Javitt, U. Heresco-Levy Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia Brain Res 1004 2004 142 147
43. G.M. Simpson, J.W.S. Angus A rating scale for extrapyramidal side effects Acta Psych Scand Suppl 212 1970 11 19
44. S.H. Snyder Forty years of neurotransmitters A personal account Arch Gen Psychiatry 59 2002 983 994
45. K. Takahashi, F. Hayashi, T. Nishikawa In vivo evidence for the link between L- and D-serine metabolism in rat cerebral cortex J Neurochem 69 1997 1286 1290
46. Y. Tanii, T. Nishikawa, A. Hashimoto, K. Takahashi Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat J Pharmacol Exp Ther 51 1994 139 154
47. G. Tsai, H. Lane, P. Yong, M. Chong, N. Lange Glycine transporter 1 inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 55 2004 452 456
48. G. Tsai, P. Yong, L.-C. Chung, N. Lange, J.T. Coyle d-serine added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 44 1998 1081 1089
49. G.E. Tsai, L. Pinchen Yang, L. Chung, I. Tsai, C. Tsai, J.T. Coyle d-serine added to clozapine for the treatment of schizophrenia Am J Psychiatry 156 1999 1822 1825